Other Events ·
On September 24, 2026, Acadia Pharmaceuticals announced Phase 3-enabling topline results from the Phase 2 RADIANT…
ACADAcadia Pharmaceuticals Inc
On September 24, 2026, Acadia Pharmaceuticals announced Phase 3-enabling topline results from the Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis. The 60 mg dose narrowly missed the primary endpoint (SAPS-H+D; p=0.0603) but achieved statistical significance on the key secondary endpoint, CGI-S-ADP (p=0.0077). The drug demonstrated a favorable safety profile with no QT prolongation or negative impact on motor symptoms. Consequently, the company plans to continue Phase 3 enrollment while removing the 30 mg dose arm from future studies. Acadia Pharmaceuticals Inc. operates in the pharmaceutical industry, developing and commercializing treatments for neurological disorders.